

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Kurt Ferston Examiner #: 75063 Date: 4/9/03
 Art Unit: 3712 Phone Number 305-0303 Serial Number: 09/834 P66
 Mail Box and Bldg/Room Location: CEL-10B14 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

 Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Model for Training of Surgical Operation of Cataract
 Inventors (please provide full names): Hideki Uneyama; Nami Nakatani

Earliest Priority Filing Date: 4/16/01

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

inject one of the substances listed in claim 1 into a model of an eye (could be a pig's or other animal's eye), specifically the lens or socket. the eyemodel has no eyeball so we not injecting it into an eyeball.

the model eye is empty before we inject them into it. See claim 1.

vitreous body = corpus vitreum
 crystalline "
 body, humor crystallinus, vitreous humor

STAFF USE ONLY

	Type of Search	Vendors and cost where applicable
Searcher: <u>Julie Walko</u>	NA Sequence (#) _____	STN <u>✓</u>
Searcher Phone #: <u>305-8587</u>	AA Sequence (#) _____	Dialog <u>✓</u>
Searcher Location: <u>CEL-2C08</u>	Structure (#) _____	Questel/Orbit _____
Date Searcher Picked Up: <u>4/10/03</u>	Bibliographic <u>✓</u>	Dr.Link _____
Date Completed: <u>4/10/03</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: <u>63m</u>	Fulltext <u>✓</u>	Sequence Systems _____
Clerical Prep Time: _____	Patent Family _____	WWW/Internet <u>✓</u>
Online Time: <u>27m</u>	Other _____	Other (specify) _____

[dp005]

Protective role of tetramethyl luteolin in experimental cataracts.

Vit Patricia ¹, Jacob Tim J C ²

¹ Universidad de Los Andes, Dpto. Ciencia de los Alimentos, Facultad de Farmacia, Mérida, Venezuela.
Fax +58-74-711802, e-mail vit@ula.ve

² Eye Research Laboratory, Physiology Unit, School of Molecular and Medical Biosciences, University of Wales, Cardiff CF1 3US, UK. Fax +44-1222-874094, e-mail jacob@cf.ac.uk

Cataract is opacification of the ocular lens. Senile and diabetic cataracts are of epidemiological interest in human populations. More than 90% of blindness due to cataracts occur in developing countries (Who, 1991). This study follows an investigation on the putative anticataract properties of stingless bee (Hymenoptera; Apidae; Meliponinae) honeys in the tropical America. Eyedrops of honey from *Melipona favosa favosa* and *Trigona (Tetragonisca) angustula angustula* are used in Venezuela for this purpose (Vit Olivier, 1994). Luteolin is characteristic in the phenolic spectra of Venezuelan honeys (Vit *et al.*, 1997) and luteolin derivatives are present in stingless bee honey (Vit *et al.*, 1998). A 20 μ g flavonoid/g honey has been reported (Ferrerres *et al.*, 1994). The anticataract activity of more active flavone substitutions has been related to the aldose reductase inhibition model for polyol cataracts (Varma and Kinoshita, 1976; Okuda *et al.*, 1982; Shimizu *et al.*, 1984). Methylation was a beneficial substitution to control cataracts (Chiou *et al.*, 1992).

In a previous work, 20 flavonoids were screened in lenses under hypotonic stress to produce experimental cataracts monitored by digital image analyses, and a group of luteolin derivatives reduced lens opacification. In this work, two pulsed stresses of different nature were produced to apply tetramethyl luteolin 10^{-5} M treatment at different timing and target region. Ovine lenses were dissected from enucleated eyes by anterior approach and equilibrated in vials containing 5 ml of culture media at 37° C for 24 h prior to the experiment. They were cultured under hyperglycemic and hypocalcemic regimes. These regimes consisted in 24 h exposure to the modified culture medium, followed by 24 h exposure to control medium. The hyperglycemic regime produced complete opacification of the posterior lens and partial anterior, while the hypocalcemic regime produced a localized posterior cup opacification. The regionalized cataract was visible during the control medium phase in both regimes. Although the opacification patterns were different, suggesting mechanisms of diverse nature for each regime, tetramethyl luteolin 10^{-5} M was effective to prevent opacification only if applied during the control medium phase. These results are in agreement with the osmotic protection exerted by flavonoids as aldose reductase inhibitors and open a second avenue of a possible flavonoid action as anticataract agents at the calcium metabolism level. Protection against opacification was complete for the hypocalcemic model and was limited to the anterior lens in the hypoglycemic model. The elucidation of underlying mechanisms causing these visual effects could be approached by selective blocking and penetration studies complemented with histological descriptions.

The regionalization experiments are useful as preliminary screening aid to visualize the location of

opacification and involved protective mechanisms, both in time and space. Interpretation of diagrams on discrete observations of the lens equatorial view, give insight on target zones that require further exploration. The clearly defined posterior band observed in the hypocalcemic regime might be related to the posterior subcapsular cataract. Therefore, this might be an adequate model to study the flavonoid effect in this type of cataract.

References

- Chiou G. C. Y., Stolowich N. J., Zheng Y. Q., Shen Z. F., Zhu M., Min Z. D., 1992. Effects of some natural products on sugar cataract studied with nuclear magnetic resonance spectroscopy. *J. Ocular Pharmacol.* **8**,115-120.
- Ferreres F., Tomás-Barberán F. A., Soler C., García-Viguera C., Ortiz A., Tomás-Barberán F. A., 1994. A simple extractive technique for honey flavonoid HPLC analysis. *Apidologie* **25**,21-30.
- Okuda J., Miwa I., Inagaki K., Horie T., Nakayama M., 1982. Inhibition of aldose reductases from rat and bovine lenses by flavonoids. *Biochem. Pharmacol.* **31**,3807-3822.
- Shimizu M., Ito T., Terashima S., Hayashi T., Arisawa M., Morita N., Kurokawa S., Ito K., Hashimoto Y., 1984. Inhibition of lens aldose reductase by flavonoids. *Phytochemistry* **23**,1885-1888.
- Varma S. D., Kinoshita J. H., 1976. Inhibition of lens aldose reductase by flavonoids -their possible role in the prevention of diabetic cataracts. *Biochem. Pharmacol.* **25**,2505-2513.
- Vit P., Soler C., Tomás-Barberán F. A., 1997. Phenolic profiles of *Apis mellifera* and *Melipona* spp. honeys from Venezuela. *Z. Lebensm. Unters. Forsch.* **204**,43-47.
- Vit P., Tomás-Barberán F. A., 1998. Flavonoids in Meliponinae honey from Venezuela, related to their botanical, geographical and entomological origin to assess their putative anticataract properties. *Z. Lebensm. Unters. Forsch.* **206**, 288-293.
- Vit Olivier P., 1994. Las abejas criollas sin aguijón. *Vida Apícola* **63**,34-42.
- WHO Memoranda, 1991. Use of intraocular lenses in cataract surgery in developing countries. *Bulletin WHO* **69**,657-666.

Comments

During 1-30 September 1998, all comments on this poster should be sent by e-mail to ecsoc@listserv.arizona.edu with dp005 as the message subject of your e-mail. After the conference, please send all the comments and reprints requests to the author.



[Advanced Search](#)

[Preferences](#)

[Language Tools](#)

[Search Tips](#)

eye model dibenzylidenesorbitol

Google Search

[Web](#) - [Images](#) - [Groups](#) - [Directory](#) - [News](#)

Searched the web for ~~eye model dibenzylidenesorbitol OR "polyhydric+acid" OR polyol OR methylbenzaldehyde~~

Xylitol

Sponsored Link

www.uniquesweet.com sugar substitute tastes great in gum, mints, bubble gum, table sugar

That Amazing Xylitol

Sponsored Link

www.xylitolnow.com Gum, mints, crystal, spray vitamin. Check out our special deals.

Did you mean: eye model **dibenzylidene sorbitol** OR "polyhydric+acid" OR polyol OR methylbenzaldehyde OR "ethyl+benzaldehyde" OR xylitol

Pathophysiology Section (continued)

Sponsored Links

... and Chader, GJ (Eds.): Progress in Retinal and **Eye** Research v ... There is a greater accumulation

of **polyol** by the ... In the galactose-fed rat **model** of diabetic ocular ...

www.nei.nih.gov/intramural/patho2.htm - 15k - [Cached](#) - [Similar pages](#)

Eye models

We have a broad variety of anatomic eye models. Worldwide shipping. AcupunctureShop.com

Interest:

[See your message here...](#)

Pathophysiology Section (continued)

... and the hypergalactosemia of the galactose-fed rat **model**. ... GJ (Eds.):

Progress in

Retinal and **Eye** Research v ... Kador, PF and Hotta, N. (Eds.): **Polyol** Pathway and ...

www.nei.nih.gov/intramural/patho4.htm - 15k - [Cached](#) - [Similar pages](#)

[[More results from www.nei.nih.gov](#)]

[PDF] Evolution of the Aldose Reductase-Related Gecko **Eye** Lens Protein ...

File Format: PDF/Adobe Acrobat - [View as HTML](#)

... The resulting **model** was energy mini- mized using the steepest descents algorithm in the ... of Recombinant Proteins PCR was performed on gecko total-**eye** cDNA using ...

davapc1.bioch.dundee.ac.uk/pdf/rhob.pdf - [Similar pages](#)

WebMedline Searching

... This makes it a good **model** for studying ... protein glycosylation, activation of the "**polyol** pathway", abnormalities ... Diabetes and **eye** specialists are thus left to ...

www.medweaver.com/cgi-bin/webmedline?type=help&u= - 23k - Apr 8, 2003 - [Cached](#) - [Similar pages](#)

Editorial board, brief details

... UV effects on mammalian tissue, especially the **eye**. ... **Model** Studies of the DNA (6-4)

Photoproduct ... and A. Gambacorta Enzymatic synthesis of **polyol**- and masked ...

www.netsci-journal.com/docs/minicv.htm - 25k - [Cached](#) - [Similar pages](#)

BioMatNet Item: FAIR-CT95-0837 - Novel **Polyol** Intermediates ...

... to currently available resins, with an **eye** towards applications ... a significant presence in the final **polyol** mixture. ... technology has resulted in two **model** polyols ...

www.nf-2000.org/secure/Fair/F334.htm - 32k - [Cached](#) - [Similar pages](#)

CWRU Department of Medicine - Clinical & Molecular Endocrinology

... 9): 1233-7, Sep 1996; Kern TS;Engerman R L. A mouse **model** of diabetic ... Current **Eye** Research ... 151-161, 1992; Kern TS;Engerman R L. Retinal **polyol** and myo-inositol in ...

www.cwr.edu/CWRU/Med/medicine/KernTS.html - 17k - [Cached](#) - [Similar pages](#)

*Inventor
Search*

5/5/1 (Item 1 from file: 350)
DIALOG(R)File 350:Derwent WPIX
(c) 2003 Thomson Derwent. All rts. reserv.

014447016 **Image available**
WPI Acc No: 2002-267719/200231
XRPX Acc No: N02-208189

Surgical model for training of surgical operation of cataract, is prepared by injecting a self-hardening chemical into the crystalline lens capsule of a pig's eye

Patent Assignee: NAKAGI N (NAKA-I); UMEYAMA H (UMEY-I); NAKAKI N (NAKA-I)

Inventor: **NAKAKI N ; UMEYAMA H**

Number of Countries: 002 Number of Patents: 002

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
US 20020028429	A1	20020307	US 2001834886	A	20010416	200231 B
JP 2001350403	A	20011221	JP 2000167371	A	20000605	200231

Priority Applications (No Type Date): JP 2000167371 A-20000605.

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
-----------	------	-----	----	----------	--------------

US 20020028429	A1		7	G09B-023/28	
----------------	----	--	---	-------------	--

JP 2001350403	A		4	G09B-023/28	
---------------	---	--	---	-------------	--

Abstract (Basic): US 20020028429 A1

NOVELTY - The model is prepared by injecting a self-hardening chemical into the crystalline **lens** capsule of a pig's **eye** .

USE - For training of surgical operation of cataract.

ADVANTAGE - Provides a training model by which the feeling of an actual surgical operation for cataract of old aged people and additionally and enucleating operation of a nucleus fallen into corpus vitreum can be learned. Improves the skill and technique of ophthalmologists, whether experienced or new in the field of **eye** surgery, using such a model. The pig's **eye** used for such purpose can be easily recycled for further use.

DESCRIPTION OF DRAWING(S) - The figure shows the drawing illustrating the preparation process of a model of **eye** with cataract.

pp; 7 DwgNo 1/3

Title Terms: SURGICAL; MODEL; TRAINING; SURGICAL; OPERATE; CATARACT;

PREPARATION; INJECTION; SELF; HARDEN; CHEMICAL; CRYSTAL; **LENS** ; CAPSULE;

PIG; **EYE**

Derwent Class: P85

International Patent Class (Main): G09B-023/28

File Segment: EngPI

Set	Items	Description
S1	74	E3,E5:E7
S2	1	AU='NAKAKI N'
S3	2	S1:S2 AND (EYE? ? OR LENS??)
S4	2	IDPAT (sorted in duplicate/non-duplicate order)
S5	1	IDPAT (primary/non-duplicate records only)

? show files

File 347:JAPIO Oct 1976-2002/Dec(Updated 030402)

(c) 2003 JPO & JAPIO

File 348:EUROPEAN PATENTS 1978-2003/Mar W05

(c) 2003 European Patent Office

File 349:PCT FULLTEXT 1979-2002/UB=20030403,UT=20030327

(c) 2003 WIPO/Univentio

File 350:Derwent WPIX 1963-2003/UD,UM &UP=200324

(c) 2003 Thomson Derwent

File 371:French Patents 1961-2002/BOPI 200209

(c) 2002 INPI. All rts. reserv.

Biblis
Patents

10/5/1 (Item 1 from file: 350)
DIALOG(R)File 350:Derwent WPIX
(c) 2003 Thomson Derwent. All rts. reserv.

014447016 **Image available**
WPI Acc No: 2002-267719/200231
XRPX Acc No: N02-208189

Surgical model for training of surgical operation of cataract, is prepared by injecting a self-hardening chemical into the crystalline lens capsule of a pig's eye

Patent Assignee: NAKAGI N (NAKA-I); UMEYAMA H (UMEY-I); NAKAKI N (NAKA-I)

Inventor: NAKAKI N; UMEYAMA H

Number of Countries: 002 Number of Patents: 002

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
US 20020028429	A1	20020307	US 2001834886	A	20010416	200231 B
JP 2001350403	A	20011221	JP 2000167371	A	20000605	200231

Priority Applications (No Type Date): JP 2000167371 A 20000605

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
-----------	------	-----	----	----------	--------------

US 20020028429	A1		7	G09B-023/28	
----------------	----	--	---	-------------	--

JP 2001350403	A		4	G09B-023/28	
---------------	---	--	---	-------------	--

Abstract (Basic): US 20020028429 A1

NOVELTY - The model is prepared by injecting a self-hardening chemical into the crystalline **lens** capsule of a pig's eye.

USE - For training of surgical operation of cataract.

ADVANTAGE - Provides a training model by which the feeling of an actual surgical operation for cataract of old aged people and additionally and enucleating operation of a nucleus fallen into **corpus vitreum** can be learned. Improves the skill and technique of ophthalmologists, whether experienced or new in the field of eye surgery, using such a model. The pig's eye used for such purpose can be easily recycled for further use.

DESCRIPTION OF DRAWING(S) - The figure shows the drawing illustrating the preparation process of a model of eye with cataract.
pp; 7 DwgNo 1/3

Title Terms: SURGICAL; MODEL; TRAINING; SURGICAL; OPERATE; CATARACT; PREPARATION; INJECTION; SELF; HARDEN; CHEMICAL; CRYSTAL; **LENS** ; CAPSULE; PIG; EYE

Derwent Class: P85

International Patent Class (Main): G09B-023/28

File Segment: EngPI

Set	Items	Description
S1	352197	EYE? ? OR LENS?? OR VITREOUS(2N)HUMOR? ? OR CORPUS()VITREU- M? ? OR (HYALOID OR CRYSTALLINE OR VITREOUS) (2N) (BODY OR BODI- ES)
S2	170	DIBENZYLIDENESORBITOL?
S3	67275	POLYHYDRIC(2N)ALCOHOL? ? OR POLYOL? ?
S4	565	METHYLBENZALDEHYDE? OR METHYL()BENZALDEHYDE?
S5	220	ETHYL()BENZALDEHYDE? OR ETHYLBENZALDEHYDE?
S6	2367	XYLITOL
S7	960	S1 AND (S2 OR S3 OR S4 OR S5 OR S6)
S8	291686	LENS?? OR VITREOUS(2N)HUMOR? ? OR CORPUS()VITREUM? ? OR (- HYALOID OR CRYSTALLINE OR VITREOUS) (2N) (BODY OR BODIES)
S9	658	S8 AND (S2 OR S3 OR S4 OR S5 OR S6)
S10	1	S9 AND IC=G09B
S11	556	S9 NOT PLASTIC()LENS
S12	380	S11 NOT CONTACT()LENS??
S13	25	S12 AND INJECT?

? show files

File 347:JAPIO Oct 1976-2002/Dec(Updated 030402)

(c) 2003 JPO & JAPIO

File 350:Derwent WPIX 1963-2003/UD,UM &UP=200324

(c) 2003 Thomson Derwent

File 371:French Patents 1961-2002/BOPI 200209

(c) 2002 INPI. All rts. reserv.

FT Patents

21/TI/1 (Item 1 from file: 348)
DIALOG(R) File 348:(c) 2003 European Patent Office. All rts. reserv.

DRUG COMPOSITION
ARZNEIMITTEL-ZUSAMMENSETZUNG
COMPOSITION MEDICAMENTEUSE

21/TI/2 (Item 2 from file: 348)
DIALOG(R) File 348:(c) 2003 European Patent Office. All rts. reserv.

NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF
CHEMISCHE VERBINDUNGEN UND DEREN PHARMAZEUTISCHE VERWENDUNGEN
COMPOSES CHIMIQUES ET UTILISATION PHARMACEUTIQUE

21/TI/3 (Item 3 from file: 348)
DIALOG(R) File 348:(c) 2003 European Patent Office. All rts. reserv.

Ophthalmic composition containing a 1,5-benzoxathiepine derivative for
treating glaucoma
Ophthalmische Zusammensetzung enthaltend ein 1,5-Benzoxathiepin-Derivat zur
Behandlung von Glaukoma
Composition ophtalmique contenant un derive benzoxathiepine-1,5 pour
traiter le glaucome

21/TI/4 (Item 4 from file: 349)
DIALOG(R) File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

2-SUBSTITUTED PIPERIDINES THAT ARE LIGANDS FOR MONOAMINE RECEPTORS AND
TRANSPORTERS
PIPERIDINES 2-SUBSTITUE, LIGANDS POUR DES RECEPTEURS ET DES TRANSPORTEURS
DE MONOAMINES

21/TI/5 (Item 5 from file: 349)
DIALOG(R) File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

COMPOSITIONS AND METHODS FOR INHIBITING PRENYLTRANSFERASES
COMPOSITIONS ET PROCEDES PERMETTANT D'INHIBER DES PRENYLTRANSFERASES

21/TI/6 (Item 6 from file: 349)
DIALOG(R) File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

INTERFERING WITH TELOMERE MAINTENANCE IN TREATMENT OF DISEASES
METHODES THERAPEUTIQUES ENTRAVANT LE MAINTIEN DES TELOMERES

21/TI/7 (Item 7 from file: 349)
DIALOG(R) File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

RAAV-VECTORED RIBOZYME COMPOSITIONS AND METHODS FOR THE TREATMENT OF
RETINAL DISEASES
COMPOSITIONS DE RIBOZYME A VECTORISATION RAAV ET PROCEDES DE TRAITEMENT DES
MALADIES RETINIENNES

21/TI/8 (Item 8 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

BREAST CANCER-ASSOCIATED GENES AND USES THEREOF
GENES ASSOCIES AU CANCER DU SEIN ET UTILISATIONS CORRESPONDANTES

21/TI/9 (Item 9 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

THIAZOLE AND OTHER HETEROCYCLIC LIGANDS FOR MAMMALIAN DOPAMINE, MUSCARINIC
AND SEROTONIN RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF
THIAZOLE ET AUTRES LIGANDS HETEROCYCLIQUES POUR RECEPTEURS ET TRANSPORTEURS
MAMMALIENS DE SEROTONINE, DE DOPAMINE ET DE LA MUSCARINE, ET METHODES
D'UTILISATION CORRESPONDANTES

21/TI/10 (Item 10 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

HETEROCYCLIC ANALGESIC COMPOUNDS AND METHODS OF USE THEREOF
COMPOSES ANALGESIQUES HETEROCYCLIQUES ET LEURS METHODES D'UTILISATION

21/TI/11 (Item 11 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

PIPERIDINE-PIPERAZINE LIGAND FOR NEUROTRANSMITTER RECEPTORS
LIGAND PIPERIDINE-PIPERAZINE POUR RECEPTEURS NEUROTRANSMETTEURS

21/TI/12 (Item 12 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

HETEROCYCLIC ANALGESIC COMPOUNDS AND METHODS OF USE THEREOF
COMPOSES HETEROCYCLIQUES ANALGESIQUES ET LEUR PROCEDE D'UTILISATION

21/TI/13 (Item 13 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

USE OF CATECHOLAMINE REUPTAKE INHIBITORS TO ENHANCE MEMORY
UTILISATION D'INHIBITEURS DE CATECHOLAMINE REUPTAKE POUR AMELIORER LA
MEMOIRE

21/TI/14 (Item 14 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

ANALGESIC DIAZABICYCLO[4.3.0]NONANES
DIAZABICYCLO[4.3.0]NONANES ANALGESIQUES

21/TI/15 (Item 15 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

ORALLY-BIOAVAILABLE FORMULATIONS OF FENTANYL AND CONGENERS THEREOF
FORMULATIONS A BIODISPONIBILITE ORALE DE FENTANYL ET DE CONGENERES

21/TI/16 (Item 16 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

4,4-DISUBSTITUTED PIPERIDINES FOR USE AS DOPAMINE, SEROTONIN AND
NOREPINEPHRINE LIGANDS
PIPERIDINES 4,4-DISUBSTITUEES LEURS PROCEDES D'UTILISATION

21/TI/17 (Item 17 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

ACE-2 MODULATING COMPOUNDS AND USE THEREOF
COMPOSES MODULANT ACE-2 ET PROCEDES D'UTILISATION ASSOCIES

21/TI/18 (Item 18 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.
METHODS AND COMPOSITIONS FOR REGULATING MEMORY CONSOLIDATION
PROCEDES ET COMPOSITIONS PERMETTANT DE REGULER LA CONSOLIDATION DE LA
MEMOIRE

21/TI/19 (Item 19 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.
ANTIPSYCHOTIC SULFONAMIDE-HETEROCYCLES, AND METHODS OF USE THEREOF
HETEROCYCLES SULFONAMIDES ANTIPSYCHOTIQUES ET LEURS METHODES D'UTILISATION

21/TI/20 (Item 20 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.
LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE
THEREOF (NEUROTRANSMISSION)
LIGANDS POUR LES RECEPTEURS DE MONOAMINE ET TRANSPORTEURS, ET PROCEDES
D'UTILISATION DE CES DERNIERS

21/TI/21 (Item 21 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.
USE OF METHYLPHENIDATE COMPOUNDS TO ENHANCE MEMORY
UTILISATION DE COMPOSES DE METHYLPHENIDATE POUR RENFORCER LA MEMOIRE

21/TI/22 (Item 22 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.
USE OF THREO-METHYLPHENIDATE COMPOUNDS TO ENHANCE MEMORY
UTILISATION DE COMPOSES DE THREO-METHYLPHENIDATE AFIN D'AMELIORER LA
MEMOIRE

21/TI/23 (Item 23 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.
ANGIOGENESIS-MODULATING COMPOSITIONS AND USES
COMPOSITIONS MODULATRICES DE L'ANGIOGENESE ET LEURS UTILISATIONS

21/TI/24 (Item 24 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

HETEROCYCLIC ANALGESIC COMPOUNDS AND METHOD OF USE THEREOF
COMPOSES ANALGESIQUES HETEROCYCLIQUES ET TECHNIQUE D'UTILISATION DE CEUX-CI

21/TI/25 (Item 25 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

PEPTIDOMIMETIC LIGANDS FOR CELLULAR RECEPTORS AND ION CHANNELS
LIGANDS PEPTIDOMIMETIQUES POUR RECEPTEURS CELLULAIRES ET CANAUX IONIQUES

21/TI/26 (Item 26 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

COMPOSITIONS FOR REGULATING MEMORY CONSOLIDATION
PROCEDES ET PREPARATIONS POUR LA REGULATION DE LA CONSOLIDATION DE LA
MEMOIRE

21/TI/27 (Item 27 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

3-SUBSTITUTED PIPERIDINES COMPRISING UREA FUNCTIONALITY, AND METHODS OF USE
THEREOF
PIPERIDINES 3-SUBSTITUEES COMPRENANT UN GROUPEMENT UREE ET PROCEDES
D'UTILISATION DE CES DERNIERES

21/TI/28 (Item 28 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

METHODS AND COMPOSITIONS FOR GENE DELIVERY
METHODES ET COMPOSITIONS D'ADMINISTRATION DE GENES

21/TI/29 (Item 29 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

22 HUMAN SECRETED PROTEINS
22 PROTEINES HUMAINES SECRETEES

21/TI/30 (Item 30 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

SPIROCYCLIC LIGANDS FOR SIGMA RECEPTORS, AND LIBRARIES AND METHODS OF USE
THEREOF
LIGANDS SPIROCYCLIQUES POUR RECEPTEURS SIGMA, BIBLIOTHEQUES ET PROCEDES
ASSOCIES

21/TI/31 (Item 31 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

METHODS AND COMPOSITIONS FOR MODULATING DRUG ACTIVITY THROUGH TELOMERE

DAMAGE
METHODES ET COMPOSITIONS DESTINEES A LA MODULATION DE L'ACTION DE
MEDICAMENTS PAR DETERIORATION DE TELOMERES

21/TI/32 (Item 32 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

METHODS AND COMPOSITIONS FOR ENHANCING DELIVERY OF THERAPEUTIC AGENTS TO
TISSUES
METHODES ET COMPOSITIONS AMELIORANT LA DIFFUSION D'AGENTS THERAPEUTIQUES A
L'INTERIEUR DE TISSUS

21/TI/33 (Item 33 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

DIARYL THIOETHERS, COMPOSITIONS AND USES THEREOF
THIOETHERS DE DIARYLE, COMPOSITIONS ET UTILISATIONS DE CES DERNIERES

21/TI/34 (Item 34 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

RECOMBINANT ADENO-ASSOCIATED VIRUS TRANSFER OF GENES AFFECTING
DEMYELINATION
TRANSFERT DE GENES PAR VIRUS ADENO-ASSOCIE RECOMBINE INFLUANT SUR LA
DEMYELINISATION

21/TI/35 (Item 35 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

COMPOSITIONS AND METHODS FOR INHIBITING FUNGAL GROWTH
COMPOSITIONS ET PROCEDES INHIBANT LA PROLIFERATION FONGIQUE

21/TI/36 (Item 36 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

TRANSGENIC ANIMALS HAVING MODIFIED i(HEDGEHOG) SIGNAL TRANSDUCTION AND USES
RELATED THERETO
ANIMAUX TRANSGENIQUES A TRANSDUCTION DU SIGNAL DU "i(PATCHED)" ET LEURS
UTILISATIONS ASSOCIEES

21/TI/37 (Item 37 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

TREATING AND DIAGNOSING MACROPHAGE-MEDIATED DISEASES USING FC RECEPTOR
LIGANDS
TRAITEMENT ET DIAGNOSTIC DES MALADIES DUES AUX MACROPHAGES AU MOYEN DES
LIGANDS DES RECEPTEURS DE FC

21/TI/38 (Item 38 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

METHODS FOR PROMOTING CELL TRANSFECTION i(IN VIVO)

PROCEDES SERVANT A PROMOUVOIR LA TRANSFECTION DE CELLULES i (IN VIVO)

21/TI/39 (Item 39 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

TRANSGENIC ANIMALS EXPRESSING HUMAN Fc RECEPTORS
ANIMAUX TRANSGENIQUES EXPRIMANT LES RECEPTEURS DE FC HUMAINS

21/TI/40 (Item 40 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

PREPARATION OF GLYCOSYLATED TUMOR NECROSIS FACTOR
PREPARATION D'UN FACTEUR DE NECROSE TUMORALE GLYCOSILE

21/TI/41 (Item 41 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

CONFORMATIONALLY CONSTRAINED PEPTIDOMIMETICS AS 'beta'-TURN TEMPLATES AND
MODULATORS OF SH3 DOMAINS
PEPTIDOMIMETIQUES A CONFORMATION LIMITEE EN TANT QUE MATRICES A
SEGMENT-'beta' ET MODULATEURS DE DOMAINES DE SH3

21/TI/42 (Item 42 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

SYNTHESIS AND USE OF THIOPHENE- AND PYRROLE-BASED HETEROAROMATIC COMPOUNDS
SYNTHESE ET UTILISATION DE COMPOSES HETEROAROMATIQUES A BASE DE THIOPHENE
ET DE PYRROLE

21/TI/43 (Item 43 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

COMPOSITIONS AND SCREENING METHODS FOR NEUTROPHIL RESPONSES
COMPOSITIONS ET PROCEDES DE DETECTION DES REPONSES DE NEUTROPHILES

21/TI/44 (Item 44 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

RING OPENING METATHESIS OF ALKENES
METATHESE D'ALCENES PAR OUVERTURE DE NOYAU

21/TI/45 (Item 45 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

FIBRONECTIN BINDING PROTEIN COMPOSITIONS, ANTIBODIES THERETO, AND METHODS
OF USE
COMPOSITIONS DE PROTEINES SE LIANT A LA FIBRONECTINE, ANTICORPS UTILISES ET
LEURS PROCEDES D'UTILISATION

21/TI/46 (Item 46 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

NOVEL CHELATORS AND COMPOSITIONS PREPARED THEREWITH
NOUVEAUX CHELATEURS ET COMPOSITIONS PREPAREES A L'AIDE DE CEUX-CI

21/TI/47 (Item 47 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

PEPTIDYL COMPOUNDS COMPRISING AN ITIM MOTIF WHICH REGULATE HEMATOPOIETIC
FUNCTION AND THEIR USE
COMPOSES DE PEPTIDYL COMPRENANT UN MOTIF STRUCTURAL ITIM REGULANT LA
FONCTION HEMATOPOIETIQUE ET LEUR UTILISATION

21/TI/48 (Item 48 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

TACK FOR INTRAOCULAR DRUG DELIVERY AND METHOD FOR INSERTING AND REMOVING
SAME
POINTE POUR L'ADMINISTRATION INTRAOCULAIRE DE MEDICAMENTS ET PROCEDE
PERMETTANT D'INTRODUIRE ET D'ENLEVER LADITE POINTE

21/TI/49 (Item 49 from file: 349)
DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.

COLLAGEN-BASED VISCOELASTIC SOLUTION FOR VISCO-SURGERY

Set	Items	Description
S1	126811	EYE? ? OR LENS?? OR VITREOUS(2N)HUMOR? ? OR CORPUS()VITREU- M? ? OR (HYALOID OR CRYSTALLINE OR VITREOUS) (2N) (BODY OR BODI- ES)
S2	112	DIBENZYLIDENESORBITOL?
S3	55970	POLYHYDRIC(2N)ALCOHOL? ? OR POLYOL? ?
S4	2072	METHYLBENZALDEHYDE? OR METHYL()BENZALDEHYDE?
S5	725	ETHYL()BENZALDEHYDE? OR ETHYLBENZALDEHYDE?
S6	5569	XYLITOL
S7	8675	S1 AND (S2 OR S3 OR S4 OR S5 OR S6)
S8	4	S7 AND IC=G09B
S9	4	IDPAT (sorted in duplicate/non-duplicate order)
S10	4	IDPAT (primary/non-duplicate records only)
S11	4818	S7 AND INJECT?
S12	4123	S11 NOT (CONTACT OR PLASTIC OR OPHTHALMIC OR SPECTACL? OR E- YEGGLASS??) (2N)LENS??
S13	2847	S12 AND (MODEL???? OR TRAIN?)
S14	2797	S13 NOT IC=G03G
S15	2776	S14 NOT IC=G02B
S16	349	S15 AND CATARACT? ?
S17	598	S7 AND INJECT?(3N)S1
S18	248	S17 NOT (CONTACT OR PLASTIC OR OPHTHALMIC OR SPECTACL? OR E- YEGGLASS??) (2N)LENS??
S19	49	S18 AND (TEACH? OR TRAIN?)
S20	49	IDPAT (sorted in duplicate/non-duplicate order)
S21	49	IDPAT (primary/non-duplicate records only)

? show files

File 348:EUROPEAN PATENTS 1978-2003/Mar W05

(c) 2003 European Patent Office

File 349:PCT FULLTEXT 1979-2002/UB=20030403,UT=20030327

(c) 2003 WIPO/Univentio

Bib 1.0
NPL

10/TI/1 (Item 1 from file: 94)
DIALOG(R)File 94:(c)2003 Japan Science and Tech Corp(JST). All rts.
reserv.

A Case of Necrotizing Sclerokeratitis Due to Extracapsular Cataract
Extraction.

10/TI/2 (Item 2 from file: 94)
DIALOG(R)File 94:(c)2003 Japan Science and Tech Corp(JST). All rts.
reserv.

Successful Treatment with Topical Chloramphenicol in a Case of MRSA Corneal
Ulcer in an Elderly Long-Term Bedridden Patient.

10/TI/3 (Item 3 from file: 94)
DIALOG(R)File 94:(c)2003 Japan Science and Tech Corp(JST). All rts.
reserv.

A case of interstitial keratitis following varicella and mumps.

Set	Items	Description
S1	1194694	EYE? ? OR LENS?? OR VITREOUS(2N)HUMOR? ? OR CORPUS()VITREU- M? ? OR (HYALOID OR CRYSTALLINE OR VITREOUS) (2N) (BODY OR BODI- ES)
S2	7	DIBENZYLIDENESORBITOL?
S3	34610	POLYHYDRIC(2N)ALCOHOL? ? OR POLYOL? ?
S4	352	METHYLBENZALDEHYDE? OR METHYL()BENZALDEHYDE?
S5	37	ETHYL()BENZALDEHYDE? OR ETHYLBENZALDEHYDE?
S6	9358	XYLITOL
S7	1864	S1 AND (S2 OR S3 OR S4 OR S5 OR S6 OR S7)
S8	3	S7 AND S1(3N)INJECT?
S9	3	RD (unique items)
S10	3	S9 NOT PY>2000

? show files

File 2:INSPEC 1969-2003/Mar W5
(c) 2003 Institution of Electrical Engineers

File 5:Biosis Previews(R) 1969-2003/Apr W1
(c) 2003 BIOSIS

File 6:NTIS 1964-2003/Apr W1
(c) 2003 NTIS, Intl Cpyrght All Rights Res

File 8:Ei Compendex(R) 1970-2003/Mar W5
(c) 2003 Elsevier Eng. Info. Inc.

File 34:SciSearch(R) Cited Ref Sci 1990-2003/Apr W1
(c) 2003 Inst for Sci Info

File 35:Dissertation Abs Online 1861-2003/Mar
(c) 2003 ProQuest Info&Learning

File 65:Inside Conferences 1993-2003/Apr W1
(c) 2003 BLDSC all rts. reserv.

File 73:EMBASE 1974-2003/Apr W1
(c) 2003 Elsevier Science B.V.

File 94:JICST-EPlus 1985-2003/Apr W1
(c)2003 Japan Science and Tech Corp(JST)

File 144:Pascal 1973-2003/Mar W5
(c) 2003 INIST/CNRS

File 155:MEDLINE(R) 1966-2003/Apr W1
(c) format only 2003 The Dialog Corp.

File 172:EMBASE Alert 2003/Apr W1
(c) 2003 Elsevier Science B.V.

File 198:Health Devices Alerts(R) 1977-2003/Apr W1
(c) 2003 ECRI-nonprft agncy

File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
(c) 1998 Inst for Sci Info

File 48:SPORTDiscus 1962-2003/Mar
(c) 2003 Sport Information Resource Centre

File 71:ELSEVIER BIOBASE 1994-2003/Apr W1
(c) 2003 Elsevier Science B.V.

File 91:MANTIS(TM) 1880-2002/Oct
2002 (c) Action Potential

File 162:CAB Health 1983-2003/Jan
(c) 2003 CAB International

File 164:Allied & Complementary Medicine 1984-2003/Apr
(c) 2003 BLHCIS

File 467:ExtraMED(tm) 2000/Dec
(c) 2001 Informania Ltd.

10/TI/1 (Item 1 from file: 442)
DIALOG(R)File 442:(c)2003 Amer Med Assn -FARS/DARS apply. All rts. reserv.

Retinal Oxalosis; A Clinicopathologic Report (CLINICOPATHOLOGIC REPORT)

10/TI/2 (Item 2 from file: 442)
DIALOG(R)File 442:(c)2003 Amer Med Assn -FARS/DARS apply. All rts. reserv.

Fluorometric Studies on the Blood-Retinal Barrier in Experimental Animals (LABORATORY SCIENCES)

Set	Items	Description
S1	89651	EYE? ? OR LENS?? OR VITREOUS(2N)HUMOR? ? OR CORPUS()VITREU- M? ? OR (HYALOID OR CRYSTALLINE OR VITREOUS) (2N) (BODY OR BODI- ES)
S2	0	DIBENZYLIDENESORBITOL?
S3	1037	POLYHYDRIC(2N)ALCOHOL? ? OR POLYOL? ?
S4	2	METHYLBENZALDEHYDE? OR METHYL()BENZALDEHYDE?
S5	1	ETHYL()BENZALDEHYDE? OR ETHYLBENZALDEHYDE?
S6	273	XYLITOL
S7	164	S1 AND (S2 OR S3 OR S4 OR S5 OR S6)
S8	2	S7 AND INJECT?(5N)S1
S9	2	RD (unique items)
S10	2	S9 NOT PY>2000

? show files

File 441:ESPICOM Pharm&Med DEVICE NEWS 2003/Apr W1
(c) 2003 ESPICOM Bus.Intell.

File 442:AMA Journals 1982-2003/Aug B1
(c)2003 Amer Med Assn -FARS/DARS apply

File 444:New England Journal of Med. 1985-2003/Apr W2
(c) 2003 Mass. Med. Soc.

File 95:TEME-Technology & Management 1989-2003/Mar W4
(c) 2003 FIZ TECHNIK

File 98:General Sci Abs/Full-Text 1984-2003/Feb
(c) 2003 The HW Wilson Co.

File 135:NewsRx Weekly Reports 1995-2003/Mar W5
(c) 2003 NewsRx

File 149:TGG Health&Wellness DB(SM) 1976-2003/Mar W5
(c) 2003 The Gale Group

File 369:New Scientist 1994-2003/Mar W4
(c) 2003 Reed Business Information Ltd.

File 370:Science 1996-1999/Jul W3
(c) 1999 AAAS